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Abstract
Background: The pathogenesis of HIV-1 glycoprotein 120 (gp120) associated neuroglial toxicity
remains unresolved, but oxidative injury has been widely implicated as a contributing factor. In
previous studies, exposure of primary human central nervous system tissue cultures to gp120 led
to a simplification of neuronal dendritic elements as well as astrocytic hypertrophy and hyperplasia;
neuropathological features of HIV-1-associated dementia. Gp120 and proinflammatory cytokines
upregulate inducible nitric oxide synthase (iNOS), an important source of nitric oxide (NO) and
nitrosative stress. Because ascorbate scavenges reactive nitrogen and oxygen species, we studied
the effect of ascorbate supplementation on iNOS expression as well as the neuronal and glial
structural changes associated with gp120 exposure.
Methods: Human CNS cultures were derived from 16–18 week gestation post-mortem fetal
brain. Cultures were incubated with 400 µM ascorbate-2-O-phosphate (Asc-p) or vehicle for 18
hours then exposed to 1 nM gp120 for 24 hours. The expression of iNOS and neuronal (MAP2)
and astrocytic (GFAP) structural proteins was examined by immunohistochemistry and
immunofluorescence using confocal scanning laser microscopy (CSLM).
Results: Following gp120 exposure iNOS was markedly upregulated from undetectable levels at
baseline. Double label CSLM studies revealed astrocytes to be the prime source of iNOS with rare
neurons expressing iNOS. This upregulation was attenuated by the preincubation with Asc-p,
which raised the intracellular concentration of ascorbate. Astrocytic hypertrophy and neuronal
injury caused by gp120 were also prevented by preincubation with ascorbate.
Conclusions: Ascorbate supplementation prevents the deleterious upregulation of iNOS and
associated neuronal and astrocytic protein expression and structural changes caused by gp120 in
human brain cell cultures.
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Introduction
Patients with HIV-1/AIDS have a high frequency of neuro-
logical complications during the course of infection [1,2].
These complications include opportunistic infections and
neoplasms. HIV-1-associated dementia (HAD) is a com-
mon neurodegenerative disease in AIDS and occurs inde-
pendent of opportunistic infections or neoplasms [3].
HIV-1 associated dementia is associated with HIV-1
encephalitis and a high brain viral burden. [4,5]. The
pathological hallmarks of HIV-1 encephalitis include
reactive astrocytosis, myelin pallor and the presence of
multinucleated giant cells [6-8]. Recent evidence suggests
that pruning of neuronal dendrites and synaptic contacts
are correlates of dementia [8,9]. Other studies have dem-
onstrated a correlation between neuronal loss and demen-
tia [10].
HIV-1 enters the brain early, within days of the initial
viremia. The virus gains access via CD4+ macrophages [7],
which migrate across the blood-brain barrier. The infec-
tion then spreads to neighbouring microglia, the only
host to productive infection in the brain. Most evidence
points to the main pathway of neuronal injury as being
indirect, through the release of toxins by activated micro-
glia and astrocytes. [7,11]. Factors such as cytokines and
shed viral proteins such as glycoprotein 120, released by
infected cells, can further activate microglia and astro-
cytes. Glycoprotein 120 (gp120) is the HIV-1 surface glyc-
oprotein responsible in part for HIV-1 binding to target
cells and is implicated as a causative factor in AIDS-related
neurotoxicity [12-14]. Very high concentrations of gp120
are required for direct neuronal injury, much higher than
the actual levels of the protein believed to be present in
vivo, lending further support to the theory that the neuro-
toxicity of gp120 is largely indirect [7]. Moreover in HAD,
apoptotic neurons do not co-localize with infected micro-
glia. [15], further implicating a multicellular pathogene-
sis. Macrophage and astrocyte activation results in
elevated levels of proinflammatory cytokines, chemok-
ines and endothelial adhesion molecules. Activated
microglia also release glutamate and other excitatory
amino acids such as quinolate and cystine [16,17]. Over-
stimulation of glutamate receptors leads to excessive cal-
cium influx and to the formation of free radicals such as
nitric oxide (NO) in neurons and astrocytes [7].
Nitric oxide is produced from the conversion of L-arginine
to L-citrulline by nitric oxide synthases (NOS) and is
involved in a number of vital physiological processes
including vasodilation and neurotransmission [18]. There
are three isoforms of the NOS enzyme; inducible NOS
(iNOS), endothelial NOS (eNOS), and neuronal NOS
(nNOS). Both the neuronal and endothelial isoforms of
NOS are activated by calcium and calmodulin [19]. How-
ever, iNOS activity is independent of calcium. Moreover,
iNOS can produce greater amounts of NO (µM rather
than pM produced by the constitutively expressed iso-
forms). Nitric oxide combines with the superoxide anion
to form the neurotoxic oxidant, peroxynitrite. Peroxyni-
trite and other reactive oxygen species are scavenged by
low molecular weight reductants such as ascorbate but
nitrosative stress occurs when these reductants have been
depleted [20]. Nitric oxide can also bind to cytochrome
oxidase, the terminal complex of the mitochondrial respi-
ratory transport chain [21]. By competing with O2, NO
reversibly inhibits cytochrome oxidase, prevents cellular
respiration and may lead to the increased generation of
superoxide anion and peroxynitrite [22]. Furthermore,
inhibition of mitochondrial oxygen uptake leads to eleva-
tion of cytosolic calcium. It has been suggested that the
elevation of cytosolic calcium facilitates mitochondrial
transition pore opening and the release of pro-apoptotic
proteins [23]. Other authors have provided evidence that
nitric oxide may mediate cytotoxicity through a number
of other pathways including DNA damage and activation
of poly (ADP-ribose) polymerase [24-28].
Previous studies have demonstrated fragmentation, vacu-
olation, varicosities, and pruning of neuronal dendrites
following exposure of primary mixed CNS cultures to
gp120 (Iskander et al.: Human CNS cultures exposed to
HIV-1 gp120 reproduce dendritic injuries of HIV-1-associ-
ated dementia. J Neuroinflammin, 2004, 1:7). These neuro-
nal injuries were accompanied by astrocytic hypertrophy
and hyperplasia, which is consistent with neuropatholog-
ical observations in HAD. [7,29-31]. The relevance of
iNOS following gp120 exposure comes in part from stud-
ies that have shown that inhibitors of iNOS mitigate some
of the effects of gp120. Many studies have reported
increased plasma cortisol levels in HIV-1 patients, in cor-
relation with the clinical progression of the disease [32]. It
was demonstrated that gp120 is able to activate the
hypothalamic-pituitary-adrenal axis through the release
of corticotropin releasing factor (CRF) [33]. However, in
the presence of a nonselective NOS inhibitor, L-NAME,
gp120 exposure was no longer sufficient to induce CRF
production [33]. Moreover, an upregulation of membrane
CD23 protein was detected in primary human astrocyte
cultures exposed to gp120. This upregulation resulted in
the production of NO and interleukin-1-beta (IL-1β),
which was prevented with the use of the iNOS inhibitor,
aminoguanidine [34]. Glutamate receptor antagonists,
NOS inhibitors, and superoxide dismutase have also been
shown to protect primary neuronal cultures from gp120
[35].
Highly active antiretroviral therapy (HAART) has met
with success in the treatment of HIV-1/AIDS, yet the effect
on the prevalence of HAD is uncertain [36]. Furthermore,
95% of the world's HIV/AIDS patients reside in thirdJournal of Neuroinflammation 2004, 1 http://www.jneuroinflammation.com/content/1/1/8
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world nations where HAART is prohibitively expensive
and plagued by barriers to distribution. We have focused
our attention on the potential therapeutic capacity of
inexpensive, readily available, non-toxic reductants such
as ascorbate (vitamin C). Post-mortem studies of patients
with HAD have revealed decreased ascorbate levels in
homogenates of the frontal cortex [37]. In a model of sep-
tic encephalopathy, our studies with rat astrocytes have
demonstrated a protective effect of intracellular ascorbate
against iNOS upregulation following exposure to bacte-
rial endotoxin lipopolysaccaride (LPS) and interferon-
gamma (IFN-γ) [38].
We report that iNOS upregulation accompanies neuronal
injury and astrocytic hypertrophy in primary human CNS
cultures following gp120 exposure. Furthermore, treat-
ment of cultures with ascorbate-2-O-phosphate (Asc-p)
prior to exposure to gp120 attenuates the upregulation of
iNOS and protects against neuronal and astrocytic
injuries.
Materials and Methods
Materials
Biotinylated secondary antibodies; Avidin-Biotin com-
plex; and fluorescein isothiocyanate (FITC) conjugated
horse anti-mouse (F1-2000) were from Vector Laborato-
ries (Chicago, IL, USA). Texas Red conjugated goat anti-
rabbit (111-075-144) was purchased from Jackson Immu-
noResearch (West Grove, PA, USA). Polyclonal anti-iNOS
antibodies were purchased from Chemicon (Mississauga,
ON, Canada). Polyclonal anti-caspase-3 antibody
(6734A1) was from PharMingen (San Diego, CA, USA).
Antibodies to glial fibrillary acidic protein (GFAP, poly-
clonal) and microtubule associated protein 2 (MAP2,
monoclonal); ascorbate-2-O-phosphate (A-8960); poly-
ornithine (C7518); anhydrous citric acid (C2404); 3,3'-
diaminobenzidine, DAB (D4293); LPS (L2880); and
phosphate buffered saline (P3813) were purchased from
Sigma Chemical Company (St Louis, MO, USA). Mono-
clonal anti-CD68 antibody was from Dako (Mississauga,
ON, Canada). Fetal bovine serum (16000-036); penicil-
lin-streptomycin solution (P-0781); Dulbecco's Modified
Eagle Medium, DMEM (10566-016); and laminin
(23017-015) were from Gibco laboratories (Burlington,
ON, Canada). IFNg (407304) was from Calbiochem (La
Jolla, CA, USA). Neural progenitor base media (NPBM)
and supplement (CC-3209) was from Bio Whittaker
(Walkersville, MD, USA). HIV-1SF2 gp120 was obtained
through the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH: from Chiron
Corporation.
Cell culturing
The cultures used for these studies are based on previously
described protocols of Pulliam [39] and Hammond. [40],
which allow for primary human CNS cultures to be main-
tained for periods as long as one month as mixed aggre-
gates. Furthermore, this technique resulted in cultures
with a high degree of neuronal differentiation.
The University of Western Ontario Ethics Review Com-
mittee approved the research protocols. Primary human
CNS cultures were prepared as previously described. [40]
from 16–18 week gestational age fetal forebrain, which
was transported in ice cold transport media (DMEM with
5% penicillin-streptomycin and 5% fetal bovine serum).
The tissue was dissected, separated from meninges and
triturated to a single cell suspension in fresh antibiotic
and serum supplemented DMEM, centrifuged and resus-
pended in NPBM. Cultures were maintained as monolay-
ers at a density of 5 × 105 cells/cm2 on poly-ornithine and
laminin coated slides for confocal scanning laser micros-
copy (CSLM) studies or as free-floating aggregates in
uncoated flasks at a density of 5 × 106 cells/ml for all other
experiments. The cultures were fed biweekly by half media
exchange and were incubated in a 37°C humidified
chamber at 5% CO2 for four weeks prior to exposure to
antioxidants and gp120. The cultures were then exposed
to 1 nM gp120 for 24 hours. Paired cultures were pre-
treated with media supplemented with 400 µM Asc-p or
with media alone for 18 hours prior to gp120 exposure in
the continued presence of Asc-p [38]. Asc-p was used in
place of ascorbic acid because of greater stability in culture
medium. It has been demonstrated that cell culture media
can catalyze the oxidation of compounds including ascor-
bate as reviewed by Halliwell. [41], resulting in cellular
effects attributable to the oxidation products. Asc-p is
taken in by the cells and converted to ascorbate intracellu-
larly thereby avoiding this potential confounder. Cultures
were run in triplicate. Prior to incubation with the cells,
neither DMEM nor NPBM contained detectable ascorbate
when assayed by high performance liquid chromatogra-
phy (HPLC) with electrochemical detection [38].
To ensure that preincubation with Asc-p alone does not
cause iNOS upregulation, duplicate subsets of one culture
were exposed to increasing concentrations of Asc-p for 18
hours and were then fixed prior to immunohistochemis-
try for iNOS. The concentrations of Asc-p examined were;
200 µM, 400 µM, 800 µM, 2000 µM and 4000 µM.
Inducible NOS knockout mouse astrocyte culture
In order to confirm the specificity of the iNOS primary
antibody, immunohistochemistry was performed on
iNOS knockout mouse astrocyte cultures. The University
of Western Ontario Animal Ethics Review Committee
approved the procedures. C57BL/6 wildtype mice and
iNOS knockout mice [42] were purchased from Jackson
Laboratory (Bar Harbor, ME, USA). The iNOS knockout
mice were backcrossed onto the C57BL/6 strain for 10Journal of Neuroinflammation 2004, 1 http://www.jneuroinflammation.com/content/1/1/8
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generations to obtain congenic knockout mice. One-day-
old mice were used as tissue donors. Primary cultures of
cerebral astrocytes were prepared as previously described
[43]. Briefly, the areas superficial to the lateral ventricles
of the cerebral hemispheres of 10 brains were dissected
and the meninges were removed. The neopalliums were
placed in 6 ml of MEM, minced with scissors and washed
3 times in MEM. The tissue was then triturated using a 10
ml serological pipette, vortexed and passed twice through
nylon sieves (pore size of 10 µm). Modified Eagle
Medium supplemented with horse serum (20%) was used
to dilute the cell suspension (12 ml for each mouse
neopallium). Three millilitres of the diluted suspension
was distributed to each 60 mm culture dish and was incu-
bated at 37°C in 5% CO2. The media was replaced every
four days with MEM supplemented with 10% horse
serum. The monolayer cultures grew to confluence within
two weeks and were then used for experiments.
Immunoperoxidase
Both monolayer and aggregate cultures were fixed in 4%
paraformaldehyde in PBS for 30 minutes at room temper-
ature. Fixed aggregates were suspended in 2.5% agar, and
embedded in paraffin. After deparaffinization, rehydra-
tion and PBS rinses, 5 µm sections were incubated at room
temperature in 3% hydrogen peroxide to quench endog-
enous peroxidase activity. Immunohistochemistry for
iNOS in paraffin sections required antigen retrieval to
adequately expose antigenic sites. Briefly, slides were
boiled for 11 minutes in a citrate buffer in a 1100W
microwave (GoldStar, MS-104YC) on high, followed by
11 minutes on medium. The citrate buffer consisted of 2.1
g anhydrous citric acid dissolved in 900 ml distilled water
with its pH adjusted to 6.0. Following three 5-minute
washes in PBS, slides were incubated in antibody diluent
composed of PBS containing 5% serum and 1% Triton X-
100 for 30 minutes. Sections were incubated with primary
antibodies dissolved in antibody diluent for 2 hours at
room temperature. In the case of iNOS detection, this
incubation proceeded overnight at 4°C. Antibody dilu-
tions were as follows: iNOS (polyclonal) at 1:250, GFAP
(polyclonal) at 1:1000, MAP2 (monoclonal) at 1:500,
CD68 (monoclonal) at 1:5000 and caspase-3 (polyclo-
nal) at 1:500. Three 5-minute PBS washes followed incu-
bation with the primary antibodies. Secondary antibodies
were applied at a dilution of 1:200 in the antibody diluent
for one half hour. Following another wash with PBS, Avi-
din-biotin complex was applied for one half hour before
washing with PBS. Diaminobenzidine (DAB) was applied
for 5–10 minutes followed by washing with PBS. Sections
were counterstained with hematoxylin in some cases,
before being dehydrated and mounted using Permount
(Xylene based mounting medium). Negative controls
underwent the same procedure, but without the primary
antibody.
Monolayers were processed for immunohistochemistry in
a similar fashion. Following fixation, monolayers were
washed three times with PBS and incubated in 3% hydro-
gen peroxide to quench endogenous peroxidase activity
before being incubated in the above mentioned antibody
diluent for 30 minutes. Cultures were then incubated for
2 hours with primary antibody dissolved in antibody dilu-
ent. The primary antibody dilutions for the monolayers
were the same as those used for the paraffin embedded
aggregate sections. Monolayers were then washed in PBS,
incubated with secondary antibodies, Avidin-biotin com-
plex, and DAB as done with the paraffin embedded sec-
tions. Following DAB incubation, monolayers were rinsed
in PBS and coverslipped with glass coverslips and fluores-
cence-preserving mounting media.
Immunofluorescence
Monolayers were fixed for 30 minutes in 4% paraformal-
dehyde. Following three 5-minute washes with PBS, the
cells were blocked for 15 minutes in antibody diluent.
Cultures were incubated for 2 hours with primary anti-
bodies in antibody diluent. MAP2 (monoclonal) was
diluted 1:500, GFAP (monoclonal) 1:100, and iNOS (pol-
yclonal) 1:250 dilution. Following washing with PBS, the
monolayers were incubated in the dark for half an hour
with Texas Red conjugated goat anti-rabbit and fluores-
cein isothiocyanate (FITC) conjugated horse anti-mouse
each diluted 1:200 in antibody diluent. Following a final
PBS wash, the monolayers were mounted directly onto
glass slides with fade resistant mounting media.
Slides were imaged on a Zeiss LSM 410 equipped with a
Krypton/Argon laser, dichroic beam splitters and barrier
emission filters needed for triple labelling. Texas Red was
excited at a wavelength of 568 nm and collected through
a long pass filter (590LP). FITC was excited with a wave-
length of 488 nm and collected with a narrow band filter
(515-540BP). Texas Red and FITC were assigned to the red
and green channels respectively of the generated RGB
image.
Measure of intracellular ascorbate
To determine the amount of ascorbate accumulated by the
cells following Asc-p preincubation, three wells of one
culture were treated with 400 µM Asc-p supplemented
media for 18 hours and three additional wells were
treated with media alone. Following 18 hours, superna-
tant was removed, the cellular fraction was homogenized
using a Mini-beadbeater (BIO SPEC products) and the
intracellular ascorbate concentration was measured using
high-performance liquid chromatography (HPLC) [38].
Intracellular ascorbate was expressed per mg cell protein,
which was measured by the Lowry method.Journal of Neuroinflammation 2004, 1 http://www.jneuroinflammation.com/content/1/1/8
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Image analysis
Digital images from ten random high power fields were
collected from each condition. The nuclei were counted
manually and the average number of nuclei per field was
calculated for each condition. There was no significant
difference in cell density between conditions. Serial sec-
tions were subsequently stained for MAP2 or GFAP with-
out counterstaining. Digital images were collected from
ten random high power fields for each antigen from each
condition. Images were converted to greyscale and Sig-
maScan Pro 5 software was used to establish an intensity
threshold to quantify the total number of MAP2 and
GFAP positive pixels. For image analysis of iNOS expres-
sion, counterstained slides were first thresholded to elim-
inate hematoxylin counterstaining after which images
were analyzed as for MAP2 and GFAP. The average area
stained per condition per field was calculated for the
iNOS, MAP2 and GFAP stained sets. In the case of caspase-
3 stained sets, the number of caspase-3 positive cells and
the number of nuclei in each field were counted manu-
ally. Statistical analysis of these data was accomplished by
one-way ANOVA using StatView software followed by a
Fisher's Protected Least Significant Difference post-hoc
test. A p-value less than 0.05 was considered significant.
Results
Gp120 dose curve response
The concentration of gp120 to use for experimentation
was determined initially by performing a dose curve
experiment using primary human CNS aggregate cultures
incubated with 0 nM, 1 nM, 10 nM, and 100 nM gp120
for 24 hours. The density and distribution of iNOS stain-
ing increased with increasing gp120 dose (data not
shown). Nuclear fragmentation and condensation
became apparent at 100 nM gp120. The 1 nM concentra-
tion was selected for further investigation because it repre-
sented the lowest concentration of gp120 to elicit a
detectable upregulation of iNOS.
iNOS upregulation associated with gp120 exposure was 
attenuated by pre-treatment with ascorbate
Intracellular ascorbate concentration of the aggregate cul-
tures was 30 +/- 11 nmol/mg protein in cells that had
been incubated with 400 µM Asc-p for 18 hours. How-
ever, ascorbate was not detected in unsupplemented cells.
Assuming the cells contain 4 µl water per mg protein, this
intracellular ascorbate concentration approximates 8 mM.
These levels of intracellular ascorbate are consistent with
previous studies with rat [38]. Following exposure to 1 nM
gp120 for 24 hours, iNOS expression was markedly
increased as detected by immunohistochemistry (figure
1a and 1b). In cultures pre-treated with Asc-p (400 µM),
the increase in iNOS expression was greatly attenuated
(figure 1c). Figure 1d is a quantitative assessment of the
amount of iNOS immunoreactivity in each condition
based on image analysis.
Pre-treatment with ascorbate attenuates neuronal 
structural damage associated with gp120 exposure
Parallel aggregate cultures exposed to 1 nM gp120, 1 nM
gp120 following Asc-p supplementation, or media alone
for 24 hours were labelled for MAP2 or GFAP. Substantial
astrocytic hypertrophy (as measured by GFAP immunore-
activity) occurred following exposure to gp120 (figure 2a
and 2b), and this was averted by Asc-p pre-treatment (fig-
ure 2c). In addition, figure 3a and 3b demonstrate the
reduction in neuronal process complexity following
gp120 exposure (MAP2 staining). In the cultures pre-
treated with Asc-p prior to gp120 exposure, MAP2 expres-
sion was preserved (figure 3c). Figures 2d and 3d are
graphical representations of these trends based on image
analysis of ten random fields in each condition from one
culture subset. In contrast to astrocytes, microglia did not
change in number or size following exposure to gp120, as
detected by immunohistochemistry with CD68. Asc-p
alone did not induce any structural injury or iNOS upreg-
ulation in the cultures.
Specificity of iNOS antibody
Wildtype and iNOS knockout mouse monolayer astro-
cytes were treated with the bacterial endotoxin lipopoly-
saccharide (LPS, 25 ng/ml) and interferon gamma (IFN-γ,
100 U/ml), or with vehicle, for 24 hours. Treatment of
wild type astrocytes with LPS+IFN-γ resulted in a marked
upregulation of iNOS as detected by immunohistochem-
istry (figure 4e) compared to untreated wild type cultures
(figure 4c). However, iNOS was not detected in either the
untreated or treated iNOS knockout astrocytes (figure 4d
and 4f), further supporting the specificity of the antibody
[44,45].
iNOS co-localizes extensively with astrocytic GFAP and 
rarely with MAP2
Confocal scanning laser microscopy was used to examine
monolayer cultures for the source of iNOS upregulation.
Almost all GFAP positive cells (astrocytes) co-expressed
iNOS (figure 5, upper 3 panels). However, there were only
rare examples of MAP2 positive cells (neurons) co-
expressing iNOS (figure 5, lower 3 panels).
Caspase-3 expression does not increase with gp120 
exposure
Aggregate cultures were stained for caspase-3 expression
to identify the presence of apoptotic cells. Gp120, with or
without Asc-p pre-treatment, had no detectable effect on
caspase-3 expression (figure 6). This suggests that gp120
did not stimulate apoptosis during the 24-hour experi-
mental period.Journal of Neuroinflammation 2004, 1 http://www.jneuroinflammation.com/content/1/1/8
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Discussion
Our in vitro observations of neuroglial injury following
gp120 exposure are reminiscent of post-mortem findings
of HAD [46,47]. This study is novel for the use of primary
human mixed CNS culture to demonstrate the upregula-
tion of iNOS in response to gp120 exposure and supports
the previous findings of iNOS upregulation in human
glial cultures exposed to gp120. [48].
iNOS upregulation following gp120 exposure was attenuated by Asc-p supplementation Figure 1
iNOS upregulation following gp120 exposure was attenuated by Asc-p supplementation. Representative images of 
control (a), gp120 exposed (b)and gp120 exposed primary mixed human CNS aggregate cultures at 4 weeks in vitro after Asc-p 
supplementation (c) demonstrate that Asc-p supplementation reduced iNOS upregulation. The cultures were examined by 
immunohistochemistry for iNOS expression (brown) with a hematoxylin counterstain (blue) for nuclei. (Bar= 40 µm). Quanti-
tative analysis of ten random fields taken from each of the three treatment groups from one culture (d) corroborated the qual-
itative trend and showed the means of control and Asc-p supplemented groups to be significantly different from cultures 
treated with gp120. Control and gp120 treated group means were significantly different at p < 0.0001, the means of the gp120 
and gp120+Asc-p groups were significantly different at p < 0.0001, and the means of control and gp120+Asc-p supplemented 
groups were significantly different (p = 0.0001). Error bars: +/- 1 standard error.
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The expression of iNOS by microglia and astrocytes is well
documented [49-51]. It has been demonstrated that astro-
cytic markers co-localize with iNOS in the setting of HIV-
1 [34,52]. Our co-localization studies using confocal
microscopy also identified astrocytes as a major source of
iNOS. The co-localization of MAP2 and iNOS, although
rare, also implies that iNOS may be produced in select
neurons. A recent study conducted by Hori et al.,
Astrocytic hypertrophy following gp120 exposure was prevented by Asc-p supplementation Figure 2
Astrocytic hypertrophy following gp120 exposure was prevented by Asc-p supplementation. Representative 
images of control (a), gp120 exposed(b) and gp120 exposed primary mixed human CNS aggregate cultures at 4 weeks in vitro 
after Asc-p supplementation (c) demonstrate that Asc-p supplementation prevented astrocytic hypertrophy. The cultures were 
examined by immunohistochemistry for increased GFAP expression (brown) indicative of astrocytic hypertrophy (arrows) 
with a hematoxylin counterstain (blue) for nuclei. (Bar= 20 µm). Quantitative analysis of ten random fields taken from each of 
the three treatment groups from one culture (d) corroborated the qualitative trend. Control and gp120 treated group means 
were significantly different at p < 0.0001, the means of the gp120 and gp120+Asc-p groups were significantly different at p = 
0.0005 while the control and gp120+Asc-p treated group means were not significantly different (p = 0.0879). Error bars: +/- 1 
standard error.
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suggested that astrocytes were responsible for the
dysregulated overproduction of NO from iNOS rather
than monocyte-derived macrophages [53], but did not
address neuronal iNOS production, which would pre-
sumably be additionally deleterious.
Not only has neuronal expression of iNOS been identified
in vitro and in animal models [54-56], but it has also been
associated recently with other human neurodegenerative
diseases. For instance, iNOS was upregulated in degener-
ated anterior horn neurons in the setting of amyotrophic
lateral sclerosis. [57]. In a study by Vodovotz et al.,
Neuronal dendritic injury following gp120 exposure was prevented by Asc-p supplementation Figure 3
Neuronal dendritic injury following gp120 exposure was prevented by Asc-p supplementation. Representative 
images of control (a), gp120 exposed (b) and gp120 exposed primary mixed human CNS aggregate cultures at 4 weeks in vitro 
after Asc-p supplementation (c) demonstrate that Asc-p supplementation protected neuronal MAP2 expression dendrites. The 
cultures were examined by immunohistochemistry for decreased MAP2 expression (brown) indicating the loss of synaptic 
complexity with a hematoxylin counterstain (blue) for nuclei. (Bar = 40 µm). Quantitative analysis of ten random fields taken 
from each of the three treatment groups from one culture (d) corroborated the qualitative trend. Control and gp120 treated 
group means were significantly different at p = 0.0002, the means of the gp120 and gp120+Asc-p groups were significantly dif-
ferent at p = 0.0012. However the control and gp120+Asc-p treated group means were not significantly different (p = 0.5052). 
Error bars: +/- 1 standard error.
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neurons with neurofibrillary tangles in affected brain
regions in patients with Alzheimer disease, expressed
iNOS [58]. Moreover, cytokines known to induce iNOS
have been shown to be elevated in the brains of patients
with Alzheimer disease, along with an increase in nitroty-
rosine staining indicative of the presence of excessive lev-
els of NO or peroxynitrite [59]. Although the presence of
iNOS immunoreactivity in neurons has been demon-
strated in Alzheimer disease [60], it has not been docu-
mented in the setting of HAD.
Nitrosative and oxidative stress have been implicated in
the pathogenesis of HAD and a number of other inflam-
matory and neurodegenerative conditions such as Alzhe-
imer disease, amyotrophic lateral sclerosis, and Parkinson
disease [61-63]. In such diseases, cellular damage can be
attributed to the nitrosation or oxidation of vital cellular
components such as lipids, proteins and DNA by reactive
nitrogen and oxygen species (RNS and ROS). Relevant
defence mechanisms include the scavenging of RNS and
ROS and their precursors, binding of metal ions needed
for catalytic formation of ROS, and up-regulation of
endogenous defences [64]. The role of the reductant
ascorbate includes the regeneration of vitamin E from its
radical and inhibition of the peroxidation of membrane
phospholipids [64]. Evidence has been presented to sug-
gest that brain ascorbate levels are decreased in the setting
of HAD [65]. In addition to causing cellular damage
directly, ROS have also been implicated as being key inter-
mediates in signalling cascades under both normal and
aberrant cellular conditions. Hydrogen peroxide has been
demonstrated to be involved in several signal transduc-
tion pathways, stimulate mitogenesis, endothelial migra-
tion and capillary tube formation, and has also been
demonstrated to enhance cellular survival at low concen-
trations as reviewed by Stone and Collins [66]. In addi-
tion, of relevance to this research, studies have shown that
Specificity of primary iNOS antibody confirmed by  immunohistochemistry Figure 4
Specificity of primary iNOS antibody confirmed by 
immunohistochemistry. GFAP immunoreactivity was 
detected in both wild type (a) and iNOS knockout (b) mouse 
astrocyte monolayer cultures confirming the presence of 
astrocytes. iNOS immunoreactivity was not detected in wild 
type (c) or iNOS knockout (d) cultures treated with vehicle 
alone. In wild type cultures treated with LPS+IFN-γ, iNOS 
immunoreactivity increased (e). However iNOS was not 
detected in iNOS knockout cultures treated with LPS+IFN-γ 
(f). Bar= 20 µm.
Astrocytes were found to be the major source of iNOS  expression Figure 5
Astrocytes were found to be the major source of 
iNOS expression. Confocal scanning laser microscopy 
studies of primary mixed human CNS monolayer cultures at 
4 weeks in vitro revealed astrocytes to be the major sources 
of iNOS with rare neurons expressing iNOS. Immunofluo-
rescence imaging by confocal microscopy was performed for 
detection of GFAP, MAP2 and iNOS antigens. Each panel of 
images shows individual fluorophores and merged fluoro-
phores with colocalization represented in yellow. Gp120 
exposed cultures show increased iNOS expression to colo-
calize extensively with the astrocytic marker GFAP (upper 3 
panels) and rarely with the neuronal marker MAP2 (lower 3 
panels). Bar = 10 µm.Journal of Neuroinflammation 2004, 1 http://www.jneuroinflammation.com/content/1/1/8
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endothelial NOS is activated by hydrogen peroxide
through defined pathways [67-69].
Inducible NOS upregulation occurs in a wide range of
neurological disorders [70,71] and conditions including
sepsis, Alzheimer dementia. [72], Parkinson disease [73],
and in response to traumatic brain injury. [74]. Both
iNOS mRNA and protein were increased in the brains of
AIDS patients that died with severe dementia compared to
those with less severe dementia or no dementia at all [75].
These in vivo observations correlate with our in vitro model
of HAD in which iNOS was upregulated in cultures
treated with gp120. Our understanding of the mechanism
of neuroglial injury in this setting and the factors involved
remains unfinished [76-81]. The present study implicates
a role for iNOS and ROS.
There have been no previous studies that have demon-
strated the protective capacity of ascorbate in the setting of
HIV-1 gp120 induced neurotoxicity and iNOS upregula-
tion. This study establishes the ability of intracellular
ascorbate to attenuate the upregulation of iNOS associ-
ated with gp120 exposure and the capacity of intracellular
ascorbate to prevent gp120 induced astrocytic
hypertrophy and neuronal dendritic injury. It is worth
noting that others have demonstrated that ascorbate
increased nitrite and nitrate production in a mouse mac-
rophage-like cell line activated with LPS and IFN-γ [82].
However, ascorbate alone exhibited no inductive activity
in the iNOS pathway. In our own experience with human
and murine CNS culture models of inflammation and
sepsis ascorbate supplementation has been consistently
associated with decreased iNOS expression [38,83].
The exact mechanism by which ascorbate is able to reduce
the upregulation of iNOS is unknown. A recent study by
Wu et al. using rat microvascular endothelial cell cultures
demonstrated that inhibition of iNOS induction by
intracellular ascorbate was attributable to the reduction of
intracellular oxidant stress, associated with attenuation of
interferon regulatory factor-1 (IRF-1) activation [83].
Interferon regulatory factor-1 and NFκB are transcription
factors with binding sites in the promotor region of the rat
iNOS gene. [84,85]. However, Wu et al. showed that
ascorbate had no effect of on LPS and LPS+IFN-γ induced
activation of NFκB [83]. Moreover, in cultured RAW 264.7
monocyte/macrophages, antioxidants were able to blunt
the DNA binding activity of IRF-1, which mediates iNOS
induction by LPS and IFN-γ [86]. Additional studies have
Caspase 3 expression was not increased 24 hours after 1 nM gp120 exposure Figure 6
Caspase 3 expression was not increased 24 hours after 1 nM gp120 exposure. There was no significant difference in 
the average percentage of caspase-3 positive cells per field in control aggregate cultures and those treated with 1 nM gp120 or 
400 µM Asc-p prior to gp120 exposure. Ten random fields of each of the three treatment groups from one culture were used 
for quantitative analysis. Error bars: +/- 1 standard error.
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demonstrated a strong association between NFκB activa-
tion and iNOS upregulation [87-93].
The neuroprotective capacity of antioxidant drugs in the
setting of neurodegenerative disease has been both
encouraging and variable. In the case of AIDS related
dementia, the antioxidant thiol thioctic acid (α-lipoic
acid) was not successful. However, deprenyl was effective
in improving cognitive function [94]. The exact mecha-
nism by which deprenyl protects cognitive function is not
known but this monoamine oxidase-B inhibitor has been
demonstrated to scavenge hydroxyl and peroxyl radicals
[68] and increase the activities of the antioxidant enzymes
superoxide dismutase and catalase [95-97]. No previous
studies have addressed the protective capacity of ascorbate
in a human in vitro model of HAD. We feel that it is impor-
tant to explore the capacity of inexpensive, non-toxic and
more accessible therapeutic agents for all patients with
HIV-1/AIDS but especially for the vast majority of patients
that cannot afford antiretroviral therapy. We have demon-
strated that intracellular ascorbate attenuates the upregu-
lation of iNOS, as well as the reduction in dendritic
complexity and astrocytic hypertrophy associated with
gp120 exposure. The effectiveness of ascorbate in the pre-
vention and treatment of HAD awaits further study in a
clinical setting.
Conclusions
The present studies demonstrate that ascorbate supple-
mentation is able to prevent the deleterious upregulation
of iNOS and associated neuronal and astrocytic protein
expression and structural changes caused by gp120 in pri-
mary human CNS cultures.
Ascorbate is a safe, readily available and inexpensive anti-
oxidant and is therefore potentially beneficial to all
patients, especially those in impoverished countries. We
recognize that our research is in vitro and that further stud-
ies are needed to confirm the findings and explore the
mechanisms underlying the phenomenon.
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